CHMP Backs AbbVie's SKYRIZI For The Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on AbbVie's SKYRIZI for treating adults with moderately to severely active ulcerative colitis. This decision is based on successful results from two Phase 3 trials, INSPIRE and COMMAND, which met primary and key secondary endpoints.
May 31, 2024 | 7:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's SKYRIZI has received a positive opinion from CHMP for treating adults with moderately to severely active ulcerative colitis, based on successful Phase 3 trials.
The positive CHMP opinion is a significant regulatory milestone for AbbVie, likely to boost investor confidence and positively impact the stock price in the short term. The successful Phase 3 trials further validate the efficacy and safety of SKYRIZI, enhancing its market potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100